vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and Meritage Homes CORP (MTH). Click either name above to swap in a different company.

Meritage Homes CORP is the larger business by last-quarter revenue ($1.4B vs $994.2M, roughly 1.4× Charles River Laboratories). Meritage Homes CORP runs the higher net margin — 17.7% vs -27.8%, a 45.5% gap on every dollar of revenue. On growth, Meritage Homes CORP posted the faster year-over-year revenue change (10.5% vs -0.8%). Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $-225.4M).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Meritage Homes Corporation is a publicly traded American real estate development company that constructs a variety of single-family detached homes across the United States. It is the fifth largest home builder in the United States, based on 2023 home sales. The company also develops active adult communities and luxury real estate in Arizona.

CRL vs MTH — Head-to-Head

Bigger by revenue
MTH
MTH
1.4× larger
MTH
$1.4B
$994.2M
CRL
Growing faster (revenue YoY)
MTH
MTH
+11.4% gap
MTH
10.5%
-0.8%
CRL
Higher net margin
MTH
MTH
45.5% more per $
MTH
17.7%
-27.8%
CRL
More free cash flow
CRL
CRL
$284.0M more FCF
CRL
$58.6M
$-225.4M
MTH

Income Statement — Q4 FY2025 vs Q2 FY2022

Metric
CRL
CRL
MTH
MTH
Revenue
$994.2M
$1.4B
Net Profit
$-276.6M
$250.1M
Gross Margin
31.5%
Operating Margin
-28.5%
23.5%
Net Margin
-27.8%
17.7%
Revenue YoY
-0.8%
10.5%
Net Profit YoY
-28.9%
49.4%
EPS (diluted)
$-5.57
$6.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
MTH
MTH
Q4 25
$994.2M
Q3 25
$1.0B
Q2 25
$1.0B
Q1 25
$984.2M
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Q1 24
$1.0B
Net Profit
CRL
CRL
MTH
MTH
Q4 25
$-276.6M
Q3 25
$54.4M
Q2 25
$52.3M
Q1 25
$25.5M
Q4 24
$-214.5M
Q3 24
$69.7M
Q2 24
$94.1M
Q1 24
$73.0M
Gross Margin
CRL
CRL
MTH
MTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
34.6%
Q2 24
34.5%
Q1 24
34.1%
Operating Margin
CRL
CRL
MTH
MTH
Q4 25
-28.5%
Q3 25
13.3%
Q2 25
9.7%
Q1 25
7.6%
Q4 24
-16.7%
Q3 24
11.6%
Q2 24
14.8%
Q1 24
12.5%
Net Margin
CRL
CRL
MTH
MTH
Q4 25
-27.8%
Q3 25
5.4%
Q2 25
5.1%
Q1 25
2.6%
Q4 24
-21.4%
Q3 24
6.9%
Q2 24
9.2%
Q1 24
7.2%
EPS (diluted)
CRL
CRL
MTH
MTH
Q4 25
$-5.57
Q3 25
$1.10
Q2 25
$1.06
Q1 25
$0.50
Q4 24
$-4.17
Q3 24
$1.33
Q2 24
$1.74
Q1 24
$1.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
MTH
MTH
Cash + ST InvestmentsLiquidity on hand
$213.8M
$272.1M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$3.2B
$3.4B
Total Assets
$7.1B
$5.3B
Debt / EquityLower = less leverage
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
MTH
MTH
Q4 25
$213.8M
Q3 25
$207.1M
Q2 25
$182.8M
Q1 25
$229.4M
Q4 24
$194.6M
Q3 24
$210.2M
Q2 24
$179.2M
Q1 24
$327.0M
Total Debt
CRL
CRL
MTH
MTH
Q4 25
$2.1B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.5B
Q4 24
$2.2B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.7B
Stockholders' Equity
CRL
CRL
MTH
MTH
Q4 25
$3.2B
Q3 25
$3.4B
Q2 25
$3.4B
Q1 25
$3.2B
Q4 24
$3.5B
Q3 24
$3.8B
Q2 24
$3.7B
Q1 24
$3.6B
Total Assets
CRL
CRL
MTH
MTH
Q4 25
$7.1B
Q3 25
$7.5B
Q2 25
$7.6B
Q1 25
$7.6B
Q4 24
$7.5B
Q3 24
$8.0B
Q2 24
$7.9B
Q1 24
$8.2B
Debt / Equity
CRL
CRL
MTH
MTH
Q4 25
0.68×
Q3 25
0.64×
Q2 25
0.70×
Q1 25
0.79×
Q4 24
0.65×
Q3 24
0.62×
Q2 24
0.65×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
MTH
MTH
Operating Cash FlowLast quarter
$147.5M
$-219.0M
Free Cash FlowOCF − Capex
$58.6M
$-225.4M
FCF MarginFCF / Revenue
5.9%
-16.0%
Capex IntensityCapex / Revenue
8.9%
0.5%
Cash ConversionOCF / Net Profit
-0.88×
TTM Free Cash FlowTrailing 4 quarters
$518.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
MTH
MTH
Q4 25
$147.5M
Q3 25
$213.8M
Q2 25
$204.6M
Q1 25
$171.7M
Q4 24
$159.4M
Q3 24
$251.8M
Q2 24
$193.5M
Q1 24
$129.9M
Free Cash Flow
CRL
CRL
MTH
MTH
Q4 25
$58.6M
Q3 25
$178.2M
Q2 25
$169.3M
Q1 25
$112.4M
Q4 24
$83.7M
Q3 24
$213.1M
Q2 24
$154.0M
Q1 24
$50.7M
FCF Margin
CRL
CRL
MTH
MTH
Q4 25
5.9%
Q3 25
17.7%
Q2 25
16.4%
Q1 25
11.4%
Q4 24
8.4%
Q3 24
21.1%
Q2 24
15.0%
Q1 24
5.0%
Capex Intensity
CRL
CRL
MTH
MTH
Q4 25
8.9%
Q3 25
3.5%
Q2 25
3.4%
Q1 25
6.0%
Q4 24
7.5%
Q3 24
3.8%
Q2 24
3.8%
Q1 24
7.8%
Cash Conversion
CRL
CRL
MTH
MTH
Q4 25
Q3 25
3.93×
Q2 25
3.91×
Q1 25
6.74×
Q4 24
Q3 24
3.61×
Q2 24
2.06×
Q1 24
1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

MTH
MTH

Home Building$1.4B100%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$9.8M1%
Financial Service$5.1M0%
Land Closing$3.4M0%

Related Comparisons